Paclitaxel-eluting stents with erodable polymer appear safe. Commentary.
Evid Based Cardiovasc Med
2005
9
4
297-300
Non-invasive imaging of glycoprotein VI binding to injured arterial lesions.
Thromb Haemost
2005
93
5
910-3
Prevention of restenosis by systemic drug therapy: back to the future?
Circulation
2005
112
18
2759-61
Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction.
Blood Coagul Fibrinolysis
2005
16
7
511-5
Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages.
Nature
2005
433
7026
647-53
Drug-eluting stents for diabetes mellitus: a rush to judgment?
J Am Coll Cardiol
2005
45
4
479-83
Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies.
Circulation
2005
111
22
2875-80
Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial.
Catheter Cardiovasc Interv
2005
65
3
374-80
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect)
Circulation
2005
112
19
2946-50
Retroviral infection and selection of culture-derived platelets allows study of the effect of transgenes on platelet physiology ex vivo and on thrombus formation in vivo.
Arterioscler Thromb Vasc Biol
2005
25
8
1750-5